AMD, Amarin And Crispr Are Three Stocks To Watch For Potentially Higher Prices

These three health and technology stocks are on the move and pointing higher.

Advanced Micro Devices Inc. AMD, +2.27% jumped 81 cents to $37.52 on 67 million shares traded Wednesday. On Tuesday, the chip maker announced Tencent TCEHY, +0.21%  will use its latest server processors. The stock has been in a steep rising channel since its recent low below $28 in early October. Next target is the rising channel top near $40.

Amarin Corp. PLC AMRN, +2.63% followed through on Wednesday, up 55 cents to $21.49 after popping 23% on Tuesday. An FDA advisory committee is scheduled to meet today to help decide the fate of the company’s fish-derived cardiovascular drug. While trading has been halted this morning in advance of the meeting, the chart points to a test of the July high in the $23.50-$24.00 zone next.

Crispr Therapeutics AG CRSP, +0.07% rose $1.42 to $55 on 1 million shares Wednesday. The move, on no news from the company, continued the gene-editing’s stock’s month-long rally from around $36. It also followed through on Tuesday’s breakout of a mini-wedge. Watch for a move to $58 next.

See Harry’s video-chart analysis on these stocks.

The writer has no holdings in any securities mentioned.

Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis and live chart presentations.

RECENT NEWS

What Advisers Misunderstand About Protection

Protection is rarely rejected outright. More often, it is misunderstood. Most advisers recognise th... Read more

Gyrostat Market Outlook: Looking Beyond The 30-day Volatility Headlines

This outlook examines how financial markets are pricing risk rather than attempting to forecast market... Read more

Gyrostat Capital Management: The Hidden Assumption In Most Portfolios - Stability

Markets do not usually fail portfolios. Assumptions do. Most portfolios are built with car... Read more

Gyrostat February Outlook: Stewardship As Risk Reprices

This monthly outlook examines how financial markets are pricing risk, rather than attempting to forecast ... Read more

Gyrostat Capital Management: Why Risk Management Is Not About Predicting Risk

Why Risk Management is Not About Predicting Risk Financial markets reward confidence, but they punish certai... Read more

Gyrostat January Outlook: Calm At Multiyear Extremes

This monthly Gyrostat Risk-Managed Market Outlook does not attempt to forecast market direction. Its p... Read more